Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
Clinical trial NCT03118817 · COMPLETED
Trial details
- NCT number
- NCT03118817
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-19
- Primary completion
- 2020-02-04
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.